⁶⁸Ga-DOTATATE PET/CT for Neuroblastoma Staging: Utility for Clinical Use

Abstract

Metaiodobenzylguanidine (MIBG) imaging has been the standard for neuroblastoma staging for many decades. Novel agents such as ¹⁸F-DOPA and ⁶⁸Ga-DOTATATE are being used nowadays in academic centers. During the coronavirus disease 2019 (COVID-19) pandemic, procurement of ¹²³I-MIBG has proved particularly challenging, necessitating the use of ⁶⁸Ga-DOTATATE PET. ⁶⁸Ga-DOTATATE is Food and Drug Administration–approved for imaging of somatostatin receptor–positive gastroenteropancreatic neuroendocrine tumors. Methods: ⁶⁸Ga-DOTATATE PET/CT imaging was performed for staging of 3 pediatric patients with neuroblastoma at our institution. A review of the literature was also completed. Results: ⁶⁸Ga-DOTATATE PET/CT scans were successfully performed on all patients. All patients showed ⁶⁸Ga-DOTATATE–avid disease. PET scans showed an excellent spatial resolution and demonstrated high accuracy in concordance with current European Association of Nuclear Medicine guidelines. Conclusion: We have presented ⁶⁸Ga-DOTATATE PET/CT imaging for staging of neuroblastoma and believe it can reliably be used as an alternative to ¹²³I-MIBG. It has technical, clinical, and practical advantages making it an attractive option. Further multicenter studies are required before it can be recommended for standard clinical use.